Lung (Non-Small Cell) Cancer: E2511 (Hematology Oncology Associates)

ECOG-ACRIN E2511: Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer


The purpose of this study to compare the effects, good and/or bad, of veliparib or a dummy pill (placebo) when combined with the standard commonly-used drugs (cisplatin and etoposide) on patients with small cell cancer of the lung or large cell neuroendocrine non-small cell cancer of the lung to find out which is better.

Patients that participate in this study will get either veliparib or the placebo, but not both. However, patients will get the standard chemotherapy drugs no matter which type of pill they are getting.

Veliparib is a drug that is expected to prevent the cancer cell ability to reverse the effect of the standard chemotherapy drugs which may be an important way by which cancer cells are able to become unresponsive to chemotherapy. Although we have evidence from laboratory testing that veliparib may make chemotherapy drugs more effective, it may or may not make cisplatin and etoposide therapy work better against small cell lung cancer or large cell neuroendocrine non-small cell lung cancer patients.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Eastern Cooperative Oncology Group
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Hospital & Clinics, Cancer Center of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office